Illés János, Jávor András, Szíjártó Elvira
Richter Gedeon Rt., Budapest.
Acta Pharm Hung. 2002;72(1):15-24.
Manufacturing of organotherapeutic products is the most long-standing activity of Gedeon Richter Ltd dating back to the establishment of the company in 1901. By the 1940s the company had manufactured and marketed about one hundred preparations containing tissue extracts from animals. As a result of the development of synthetic molecules, organic therapy fell into the background after World War II. Although the company followed this tendency, it continued manufacturing some organotherapeutic products as well in accordance with the requirements of the time. Since the 1950s the researchers of the company have worked on the research of glycosaminoglycans introducing the manufacture of heparin, and followed by the research of hyaluronic acid (hyaluronan) in the middle of the 1980s. In the human body hyaluronan is one of the main components of the extracellular matrix, where both in passive and active manner it affects the cellular functions through its viscoelastic molecular property and hyaluronan receptors of cells. In certain therapeutic fields such as dermatology, ophthalmology, surgery and rheumatology, these biological features of hyaluronan are used. Although most of the hyaluronan products contain sodium-hyaluronate (Na-Hy), Richter's researchers found that another metal salt of hyaluronic acid such as zinc-hyaluronate (Zn-Hy) might be more favourable in some therapeutic areas than Na-Hy. Based on this theory, Gedeon Richter Ltd. developed its original zinc associate of hyaluronic acid. It is marketed under the trade name of Curiosin intended for dermatological application including promoting of wound healing. According to the results of preclinical studies on wound healing the pharmacological profile of Zn-Hy was more favourable than that of Na-Hy, proving the free radical scavenging, antioxidant, proinflammatory effects of Zn-Hy as well as the acceleration of chronic wound healing. In clinical studies Curiosin showed its efficacy in the healing of chronic and acute wounds.
器官治疗产品的生产是吉瑞大药厂(Gedeon Richter Ltd)最悠久的业务活动,可追溯到1901年公司成立之时。到20世纪40年代,该公司已生产并销售了约一百种含有动物组织提取物的制剂。由于合成分子的发展,二战后器官疗法逐渐退居幕后。尽管公司顺应了这一趋势,但仍根据当时的需求继续生产一些器官治疗产品。自20世纪50年代以来,该公司的研究人员一直致力于糖胺聚糖的研究,推出了肝素的生产,随后在20世纪80年代中期开展了透明质酸(玻璃酸)的研究。在人体中,透明质酸是细胞外基质的主要成分之一,它通过其粘弹性分子特性和细胞的透明质酸受体,以被动和主动的方式影响细胞功能。在某些治疗领域,如皮肤科、眼科、外科和风湿病学中,会利用透明质酸的这些生物学特性。尽管大多数透明质酸产品含有透明质酸钠(Na-Hy),但吉瑞大药厂的研究人员发现,透明质酸的另一种金属盐,如透明质酸锌(Zn-Hy),在某些治疗领域可能比Na-Hy更具优势。基于这一理论,吉瑞大药厂开发了其原创的透明质酸锌化合物。它以Curiosin的商品名销售,用于皮肤科应用,包括促进伤口愈合。根据伤口愈合的临床前研究结果,Zn-Hy的药理特性比Na-Hy更有利,证明了Zn-Hy的自由基清除、抗氧化、促炎作用以及对慢性伤口愈合的加速作用。在临床研究中,Curiosin显示出其在慢性和急性伤口愈合方面的疗效。